medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 4

<< Back Next >>

Rev Mex Urol 2020; 80 (4)

Human papillomavirus: Microbiology, association with penile cancer, and characteristics of the vaccine

Rengifo-Rodríguez JE, Osorio JC, García-Perdomo HA

Language: Spanish
References: 46
Page: 1-10
PDF size: 133.55 Kb.


ABSTRACT

Over the past two decades, human papillomavirus (HPV) has been an important object of study due to its causal relation to cervical cancer and its association as a risk factor for anogenital neoplasias, especially penile cancer (PC).
The molecular study of HPV and the identification of essential proteins led to the development of the vaccine, and a clear epidemiologic relation between HPV and PC has also been identified. With respect to the molecular aspect of that association, the alteration of the P16 cellular pathway by the oncoproteins of the virus is evident, but it is not thought to be the only pathogenic mechanism. The vaccine appears to be effective in preventing HPV infection but there is not sufficient evidence that it protects against PC.
Therefore, more research is needed, both in the clinical area, to determine whether the vaccine is definitively effective/efficacious in the prevention of PC, and in molecular biology, studying the molecular mechanisms involved in the pathogeny of that neoplasia


REFERENCES

  1. Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human Papillomavirus–Attributable Cancers — United States, 2012–2016. MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):724–8. doi: https:// dx.doi.org/10.15585%2Fmmwr.mm6833a3

  2. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global Burden of Human Papillomavirus and Related Diseases. Vaccine. 2012 Nov 20;30:F12–23. doi: https://doi.org/10.1016/j. vaccine.2012.07.055

  3. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017 Apr 1;3(4):524–48. doi: https:// doi.org/10.1001/jamaoncol.2016.5688

  4. Deshmukh AA, Tanner RJ, Luetke MC, Hong Y-R, Sonawane Deshmukh K, Mainous AG. Prevalence and Risk of Penile Human Papillomavirus Infection: Evidence From The National Health and Nutrition Examination Survey 2013–2014. Clin Infect Dis. 2017 May 15;64(10):1360–6. doi: https://doi. org/10.1093/cid/cix159

  5. Cates W. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7. doi: https://doi. org/10.1097/00007435-199904001-00002

  6. Diorio GJ, Leone AR, Spiess PE. Management of Penile Cancer. Urology. 2016 Oct;96:15–21. doi: https://doi.org/10.1016/j.urology.2015.12.041

  7. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, et al. Human Papillomavirus and Related Diseases Report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2019 Jun p. 307. Available from: https://hpvcentre.net/statistics/reports/ XWX.pdf

  8. Syrjänen S, Syrjänen K. The History of Papillomavirus Research. Cent Eur J Public Health. 2008;16:S7–41.

  9. Bernard H-U, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers E-M. Classification of Papillomaviruses (PVs) Based on 189 PV Types and Proposal of Taxonomic Amendments. Virology. 2010 May 25;401(1):70–9. doi: https:// dx.doi.org/10.1016%2Fj.virol.2010.02.002

  10. Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013 Oct;445(1–2):21–34. doi: https://doi. org/10.1016/j.virol.2013.06.007

  11. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Reviews in Medical Virology. 2015;25(S1):2–23. doi: https://doi.org/10.1002/rmv.1822

  12. Palefsky JM, Holly E. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1995;

  13. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology. 1989 Oct 1;63(10):4417–21.

  14. Roman A, Munger K. The papillomavirus E7 proteins. Virology. 2013 Oct;445(0):138–68. doi: https://dx.doi.org/10.1016%2Fj.virol.2013.04.013

  15. Duensing S, Münger K. Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. International Journal of Cancer. 2004;109(2):157–62. doi: https://doi. org/10.1002/ijc.11691

  16. Strati K. Changing Stem Cell Dynamics during Papillomavirus Infection: Potential Roles for Cellular Plasticity in the Viral Lifecycle and Disease. Viruses. 2017 Aug;9(8):221. doi: https://doi.org/10.3390/v9080221

  17. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different Heparan Sulfate Proteoglycans Serve asCellular Receptors for HumanPapillomaviruses. Journal of Virology. 2003 Dec 15;77(24):13125–35. doi: https://doi. org/10.1128/JVI.77.24.13125-13135.2003

  18. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus. J Virol. 2009 Mar;83(5):2067–74. doi: https:// dx.doi.org/10.1128%2FJVI.02190-08

  19. Selinka H-C, Florin L, Patel HD, Freitag K, Schmidtke M, Makarov VA, et al. Inhibition of Transfer to Secondary Receptors by Heparan Sulfate-Binding Drug or Antibody Induces Noninfectious Uptake of Human Papillomavirus. J Virol. 2007 Oct;81(20):10970–80. doi: https:// dx.doi.org/10.1128%2FJVI.00998-07

  20. Conway MJ, Meyers C. Replication and Assembly of Human Papillomaviruses. J Dent Res. 2009 Apr;88(4):307–17. doi: https:// dx.doi.org/10.1177%2F0022034509333446

  21. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006 May;110(5):525–41. doi: https:// doi.org/10.1042/CS20050369

  22. Stanley MA. Epithelial Cell Responses to Infection with Human Papillomavirus. Clin Microbiol Rev. 2012 Apr;25(2):215–22. doi: https://dx.doi.org/10.1128%2FCMR.05028-11

  23. Burd E. Human papillomavirus and cervical cancer. Clin Mikrobiol Rev. 16: 1—17. 2003.

  24. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002 Jan;2(1):59–65. doi: https:// doi.org/10.1038/nrc700

  25. Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park, NY). 2016 Mar;30(3):245–9.

  26. Mammas IN, Spandidos DA, Sourvinos G. Genomic diversity of human papillomaviruses (HPV) and clinical implications: an overview in adulthood and childhood. Infect Genet Evol. 2014 Jan;21:220–6. doi: https://doi. org/10.1016/j.meegid.2013.11.002

  27. Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20(1):145–58. doi: https://doi. org/10.1016/S1470-2045(18)30682-X

  28. Emmanuel A, Nettleton J, Watkin N, Berney DM. The molecular pathogenesis of penile carcinoma—current developments and understanding. Virchows Arch. 2019 Oct 1;475(4):397–405. doi: https://doi. org/10.1007/s00428-019-02607-8

  29. Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol. 2007 May;8(5):420– 9. doi: https://doi.org/10.1016/S1470- 2045(07)70137-7

  30. Protzel C, Spiess PE. Molecular Research in Penile Cancer—Lessons Learned from the Past and Bright Horizons of the Future? Int J Mol Sci. 2013 Sep 26;14(10):19494–505. doi: https:// dx.doi.org/10.3390%2Fijms141019494

  31. Adashek JJ, Necchi A, Spiess PE. Updates in the molecular epidemiology and systemic approaches to penile cancer. Urologic Oncology: Seminars and Original Investigations. 2019 Jul;37(7):403–8. doi: https://doi. org/10.1016%2Fj.urolonc.2019.04.012

  32. Poetsch M, Hemmerich M, Kakies C, Kleist B, Wolf E, vom Dorp F, et al. Alterations in the tumor suppressor gene p16INK4Aare associated with aggressive behavior of penile carcinomas. Virchows Arch. 2011 Feb 1;458(2):221–9. doi: https://doi.org/10.1007/s00428-010-1007-4

  33. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011 Mar 4;144(5):646–74. doi: https://doi. org/10.1016/j.cell.2011.02.013

  34. Peter M, Rosty C, Couturier J, Radvanyi F, Teshima H, Sastre-Garau X. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene. 2006 Sep 28;25(44):5985–93. doi: https://doi. org/10.1038/sj.onc.1209625

  35. Chipollini J, Chaing S, Azizi M, Kidd LC, Kim P, Spiess PE. Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets. Int J Mol Sci. 2017 Aug 16;18(8). [accessed 6 May 2020] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5578166/

  36. Agarwal G, Gupta S, Spiess PE. Novel targeted therapies for the treatment of penile cancer. Expert Opinion on Drug Discovery. 2014 Aug 1;9(8):959–68. doi: https://doi.org/10.1517/1 7460441.2014.925875

  37. Guimerà N, Lloveras B, Lindeman J, Alemany L, van de Sandt M, Alejo M, et al. The occasional role of low-risk human papillomaviruses 6, 11, 42, 44, and 70 in anogenital carcinoma defined by laser capture microdissection/ PCR methodology: results from a global study. Am J Surg Pathol. 2013 Sep;37(9):1299– 310. doi: https://doi.org/10.1097/ PAS.0b013e31828b6be4

  38. Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196–204. doi: https://doi. org/10.1016/j.ygyno.2017.04.004

  39. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebocontrolled phase 2b trial. Lancet. 2015 Nov 21;386(10008):2078–88. doi: https://dx.doi.or g/10.1016%2FS0140-6736(15)00239-1

  40. Granadillo M, Torréns I. Human papillomavirus vaccines: current status and perspectives. Biotecnologia Aplicada. 2008;25(1):1–6.

  41. Stillo M, Santisteve PC, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opinion on Drug Safety. 2015 May 4;14(5):697–712. doi: https://doi.org/10.1517 /14740338.2015.1013532

  42. Stanley M. HPV - immune response to infection and vaccination. Infect Agents Cancer. 2010 Oct 20;5(1):19. doi: https://doi.org/10.1186/1750- 9378-5-19

  43. Douglawi A, Masterson TA. Updates on the epidemiology and risk factors for penile cancer. Transl Androl Urol. 2017 Oct;6(5):785–90. doi: https://dx.doi.org/10.21037%2Ftau.2017.05.19

  44. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med. 2011 Feb 3;364(5):401–11. doi: https:// dx.doi.org/10.1056%2FNEJMoa0909537

  45. Harder T, Wichmann O, Klug SJ, van der Sande MAB, Wiese-Posselt M. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med. 2018 Jul 18;16. [accessed 6 May 2020] Available from: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC6050686/

  46. Voris BRI, Visintin CDN, Reis LO, Voris BRI, Visintin CDN, Reis LO. HPV vaccination is fundamental for reducing or erradicate penile cancer | Opinion: YES. International braz j urol. 2018 Oct;44(5):859–61. doi: https://doi. org/10.1590/s1677-5538.ibju.2018.05.02




2020     |     www.medigraphic.com